Medsider

Check out @scottnelsonlive’s interview with #LightForceBraces CEO Alfred Griffin: medsider.com/interviews/alf…

1/2 “Building it once is easy. Building it a million times is hard.” LightForce didn’t win with a novel idea. They won by building a system to scale mass customization. Why this eventually became the real moat. 👇

2/2 Nearly 80% of prescribing physicians first heard about Osteoboost from their patients. Check out @scottnelsonlive’s new interview with Laura Yecies: medsider.com/interviews/lau…

1/2 Most medtech companies sell to physicians first. @osteoboost did the opposite. CEO @lyecies turned early patient demand into a ‘Founders Program’ — and those patients became the company’s sales force. How patient pull can drive physician adoption… 👇

2/2 Consistent outcomes, reliability, and patient experience matter more than novelty in high-risk procedures. Check out @scottnelsonlive’s new interview with Stephen here shorturl.at/LQtwX

1/2 Innovation in medtech shouldn’t force physicians to relearn their procedure. As Secure Closure CEO Stephen Belcher puts it: “We’re using a method physicians are already familiar with — but changing how the device works to improve reliability.”👇

2/2 SonoVascular CEO Daniel Estay shares how he evaluates new opportunities — and why picking the right first indication can shape everything that follows. Check out @scottnelsonlive’s new interview with Dan: medsider.com/interviews/dan…

1/2 Differentiated technology doesn’t guarantee a sustainable medtech company. What actually determines whether a startup survives? Not just whether the device works — but whether the market is big enough, investable, and aligned with your tech’s current capabilities. 👇

2/2 Check out @scottnelsonlive’s full conversation with Matthias here: medsider.com/interviews/mat…

1/2 Matthias Hofmann, CEO of @Eyebot, shared how they validated market pull. They put a scrappy prototype in a mall with a “Free vision test” sign. Result: 60–100 people showed up daily. Real-world traction is the strongest signal for potential investors. 👇

Check out @scottnelsonlive’s new interview with Max: medsider.com/interviews/max…

1/2 A leadership lesson from @CMRSurgical CEO Max Colella: Startup speed is only achieved when you can actively remove the bureaucracy inherited from big-company playbooks. Why stripping processes can be just as important as building a strategy. 👇🏼

2/2 Check out @scottnelsonlive’s new interview with Rick Bente below. 👇 medsider.com/interviews/ric…

1/2 A design lesson from Rick Bente, co-founder & CEO of Indomo: At-home medical devices should be hard to misuse — not “fixed” later with better instructions. Why engineering decisions should reduce the burden on the user. 👇

2/2 That’s why commercialization starts much earlier than most teams think. Check out @scottnelsonlive’s new interview with Shaun 👇🏼 medsider.com/interviews/sha…

1/2 A commercial lesson from Shaun Bagai, CEO of @RenovoRx: Clinical trials require the same level of intentionality as selling. Enrollment depends on relationships, follow-through, and understanding who influences decisions. 👇🏼

2/2 Check out @scottnelsonlive’s new interview with SynerFuse CEO Justin Zenanko below. 👇 medsider.com/interviews/jus…

1/2 A fundraising lesson from Justin Zenanko, CEO of SynerFuse: Private capital isn’t just about extending runway. Used well, it lets you hit real clinical milestones before giving up control to VCs. Why timing beats valuation early. 👇

2/2 Check out @scottnelsonlive’s new interview with Marina Pavlovic Rivas 👇🏼 medsider.com/interviews/mar…

1/2 A useful design lesson from @data_marina, CEO of @elidothealth: Set behavioral benchmarks early and let them drive technical decisions. “Easy as brushing teeth” + “priced like a cup of coffee” became hard filters, not slogans. Why adoption starts with design constraints.👇